ArticleAnimal microbiome2025
Gut dysbiosis after successive administration of florfenicol-medicated feed alters intestinal inflammatory response and growth patterns in healthy Atlantic salmon (Salmo salar).
Article in Animal microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Inclusion of Supercritical Fluid Extract ofAntioxidants (Basel, Switzerland) · 2026Article
- Antimicrobial Resistance and Associated Genetic Determinants ofAntibiotics (Basel, Switzerland) · 2026Article
- Probiotics in Mitigating Pesticide Toxicity in Teleost Fish: Mechanisms and Prospects.Probiotics and antimicrobial proteins · 2026Review
- Effects of Florfenicol on Intestinal Structure, Microbial Community and Antibiotic Resistance Genes inMicroorganisms · 2026Article
- Antibiotic use in Chilean salmon aquaculture: antimicrobial resistance, sustainability, and One Health implications.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSuccessive treatments with florfenicol-medicated feed are the primary strategy for controlling bacterial diseases in salmonid production in Chile. However, it is well established that antibiotic administration in the diet can cause dysbiosis in the intestinal microbiota, which in turn promotes inflammatory processes with potential negative effects on nutrient absorption.
methodsIn this study, we evaluated the impact of repeated use of florfenicol-medicated diets on the composition and diversity of the intestinal microbiota, its influence on the inflammatory response of the distal intestine, and growth performance in healthy Atlantic salmon.
resultsOur findings revealed an increase in the abundance of bacterial genera considered opportunistic pathogens in this species. At the immunological level, although florfenicol initially induced an anti-inflammatory state in the intestine, a subsequent increase in the expression of pro-inflammatory cytokines was recorded. Additionally, goblet cells reduced mucin production, and significant morphological lesions were observed in the distal intestinal mucosa after repeated antibiotic exposure. While florfenicol administration at doses of 15 and 30 mg/kg slightly improved weight gain rate, specific growth rate, feed conversion efficiency, and condition factor during the treatment period, these effects were not sufficient to consider its use as a growth-promoting strategy.
conclusionsOur results suggest that, although healthy Atlantic salmon may experience a temporary improvement in growth and well-being while consuming florfenicol-medicated diets, repeated exposure leads to microbiota alterations and severe intestinal tissue damage. This may increase susceptibility to infections by opportunistic pathogens, facilitating superinfection processes and promoting greater antibiotic use, ultimately compromising the sustainability of the industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.